Company Data
BioLineRx Ltd.
Ticker
BLRX
Current Price
$3.59 -7.47%
Market Cap
$12.8M
Price Target
Refer to Report
Volume
100.5K
52wk Range
$3.2401 - $57.6
Overview
BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates – Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.